At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Maha Hussain presents results from a long-term, multicenter Phase III international clinical trial comparing two common therapies for men with hormone-sensitive metastatic prostate cancer.

Results from the study show that intermittent hormonal therapy is less effective than continuous hormonal therapy in men with minimal disease spread.